Evidence map›Paper›PMID 39175944›Full record

ArticleBrain communications2024

Cortical CD200-CD200R and CD47-SIRPα expression is associated with multiple sclerosis pathology.

Aletta M R van den Bosch, Dennis Wever, Pleun Schonewille, Sabine L Schuller, Joost Smolders, Jörg Hamann, Inge Huitinga

Abstract read
In one paragraph

Article in Brain communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Aletta M R van den BoschNeuroimmunology Research Group, Netherlands Institute for Neuroscience, Amsterdam, 1105 BA, The Netherlands.ORCID https://orcid.org/0000-0001-8886-8928
Dennis WeverNeuroimmunology Research Group, Netherlands Institute for Neuroscience, Amsterdam, 1105 BA, The Netherlands.
Pleun SchonewilleNeuroimmunology Research Group, Netherlands Institute for Neuroscience, Amsterdam, 1105 BA, The Netherlands.
Sabine L SchullerNeuroimmunology Research Group, Netherlands Institute for Neuroscience, Amsterdam, 1105 BA, The Netherlands.
Joost SmoldersNeuroimmunology Research Group, Netherlands Institute for Neuroscience, Amsterdam, 1105 BA, The Netherlands.ORCID https://orcid.org/0000-0001-9766-8661
Jörg HamannNeuroimmunology Research Group, Netherlands Institute for Neuroscience, Amsterdam, 1105 BA, The Netherlands.ORCID https://orcid.org/0000-0002-9448-1727
Inge HuitingaNeuroimmunology Research Group, Netherlands Institute for Neuroscience, Amsterdam, 1105 BA, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Control of microglia activity through CD200-CD200R and CD47-SIRPα interactions has been implicated in brain homeostasis. Here, we assessed CD200, CD47, CD200R and SIRPα expression with qPCR and immunohistochemistry in multiple sclerosis (MS) normal-appearing cortical grey matter (NAGM), normal-appearing white matter (NAWM), cortical grey matter (GM) lesions and perilesional GM, and compared this to control GM and white matter (WM), to investigate possible altered control of microglia in MS. In MS NAGM, CD200 expression is lower compared with control GM, specifically in cortical layers 1 and 2, and CD200 expression in NAGM negatively correlates with the cortical lesion rate. Interestingly, NAGM and NAWM CD200 expression is positively correlated, and NAGM CD200 expression negatively correlates with the proportion of active and mixed WM lesions. In GM lesions, CD200 and CD47 expressions are lower compared with NAGM and perilesional GM. CD200R expression is lower in MS NAGM, whereas SIRPα was increased in and around GM lesions. Taken together, our data indicate that CD200 and CD47 play a role in GM MS lesion formation and progression, respectively, and that targeting CD200 pathways may offer therapeutic avenues to mitigate MS pathology in both WM and GM.

Indexed as

immune inhibitionmultiple sclerosisnormal-appearing grey matter

Identifiers

PMID39175944
PMCPMC11339711

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.